NEW YORK (GenomeWeb News) - Genizon Biosciences said today it has partnered with the Canadian company Neuropsychiatrie, Decouverte & Innovation to conduct further genome-wide research on schizophrenia-related genes Genizon has discovered.
Earlier this year, Genizon identified multiple genes associated with schizophrenia in a genome-wide association study using DNA samples from patients from the Quebec Founder Population.
Under the agreement with NDEI, the company will provide Genizon with a second set of samples from the Quebec Founder Population that it will use for further research.
NDEI was founded in 2002 as a spinoff company of the Centre de Recherche Universite Laval Robert-Giffard.
“We expect the results of these studies to lead to a new generation of safer and more effective treatments tailored to individual schizophrenia patients,” said Michel Maziade, a scientist at the University of Laval, which will provide access to the samples.
Financial terms of the agreement were not released.